LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 35

Search options

  1. Article ; Online: Spinal Stroke: Outcome Attenuation by Erythropoietin and Carbamylated Erythropoietin and Its Prediction by Sphingosine-1-Phosphate Serum Levels in Mice.

    Koepke, Leon-Gordian / Schwedhelm, Edzard / Ibing, Wiebke / Oberhuber, Alexander / Daum, Guenter / Vcelar, Brigitta / Schelzig, Hubert / Simon, Florian

    International journal of molecular sciences

    2022  Volume 23, Issue 17

    Abstract: Spinal strokes may be associated with tremendous spinal cord injury. Erythropoietin (EPO) improves the neurological outcome of animals after spinal cord ischemia (SCI) and its effects on ischemia-induced endoplasmic reticulum (ER) stress and the unfolded ...

    Abstract Spinal strokes may be associated with tremendous spinal cord injury. Erythropoietin (EPO) improves the neurological outcome of animals after spinal cord ischemia (SCI) and its effects on ischemia-induced endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) are considered possible molecular mechanisms. Furthermore, sphingosin-1-phosphate (S1P) is suggested to correlate with SCI. In this study, the effect of recombinant human EPO (rhEPO) and carbamylated EPO (cEPO-Fc) on the outcome of mice after SCI and a prognostic value of S1P were investigated. SCI was induced in 12-month-old male mice by thoracic aortal cross-clamping after administration of rhEPO, cEPO-Fc, or a control. The locomotory behavior of mice was evaluated by the Basso mouse scale and S1P serum levels were measured by liquid chromatography-tandem mass spectrometry. The spinal cord was examined histologically and the expressions of key UPR proteins (ATF6, PERK, and IRE1a, caspase-12) were analyzed utilizing immunohistochemistry and real-time quantitative polymerase chain reaction. RhEPO and cEPO-Fc significantly improved outcomes after SCI. The expression of caspase-12 significantly increased in the control group within the first 24 h of reperfusion. Animals with better locomotory behavior had significantly higher serum levels of S1P. Our data indicate that rhEPO and cEPO-Fc have protective effects on the clinical outcome and neuronal tissue of mice after SCI and that the ER is involved in the molecular mechanisms. Moreover, serum S1P may predict the severity of impairment after SCI.
    MeSH term(s) Animals ; Caspase 12 ; Epoetin Alfa ; Erythropoietin/analogs & derivatives ; Erythropoietin/pharmacology ; Humans ; Infant ; Lysophospholipids ; Male ; Mice ; Neuroprotective Agents/pharmacology ; Recombinant Proteins/pharmacology ; Sphingosine/analogs & derivatives ; Spinal Cord Injuries/metabolism ; Spinal Cord Ischemia ; Stroke/drug therapy
    Chemical Substances Lysophospholipids ; Neuroprotective Agents ; Recombinant Proteins ; carbamylated erythropoietin ; Erythropoietin (11096-26-7) ; sphingosine 1-phosphate (26993-30-6) ; Epoetin Alfa (64FS3BFH5W) ; Caspase 12 (EC 3.4.22.-) ; Sphingosine (NGZ37HRE42)
    Language English
    Publishing date 2022-08-23
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms23179558
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells.

    Bolger, Gordon T / Licollari, Albert / Bagshaw, Richard / Tan, Aimin / Greil, Richard / Vcelar, Brigitta / Majeed, Muhammed / Sordillo, Peter

    Anticancer research

    2019  Volume 39, Issue 3, Page(s) 1161–1168

    Abstract: Background/aim: Curcumin is being widely investigated for its anticancer properties and several studies in the literature suggest that curcumin is distributed to a higher degree in cancer cells compared to normal cells. The goal of this study was to ... ...

    Abstract Background/aim: Curcumin is being widely investigated for its anticancer properties and several studies in the literature suggest that curcumin is distributed to a higher degree in cancer cells compared to normal cells. The goal of this study was to investigate the disposition of curcumin in the form of Lipocurc™ in multiple myeloma (MM)-causing plasma cell lines and B-lymphocytes from healthy individuals and compare the uptake to previously published data for red blood cells (RBCs), peripheral blood mononuclear cells (PBMCs) from healthy individuals and PBMCs from patients with chronic lymphocytic leukemia (CLL-cells).
    Materials and methods: Two MM-producing cell lines were studied: RPMI-8266, an IgG lambda cell line, and NCL-H929, an IgA kappa line. The distribution of liposomal curcumin and its metabolism to the major stable metabolite tetrahydrocurcumin (THC) were measured in vitro in the cell lines and B-lymphocytes. The cells were incubated in plasma protein-supplemented media with liposomal curcumin (Lipocurc™) for 15 min at 37°C and the levels of curcumin and THC in cells and medium were determined by liquid chromatography tandem mass spectrometry.
    Results: Extremely intense uptake was seen in both MM lines compared to that in B-lymphocytes and previously published data in RBCs, PBMCs and CLL cells. The levels of curcumin in RPMI-8266 and NCI-H929 cells were 14,225±847 and 12,723±500 pg/10
    Conclusion: The extremely intense uptake of curcumin (as Lipocurc™) in both MM lines further suggests that Lipocurc™ should be investigated in the treatment of patients with this disease.
    MeSH term(s) Antineoplastic Agents/administration & dosage ; B-Lymphocytes/metabolism ; Cell Line, Tumor ; Curcumin/administration & dosage ; Erythrocytes/metabolism ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Liposomes ; Multiple Myeloma/metabolism
    Chemical Substances Antineoplastic Agents ; Liposomes ; Curcumin (IT942ZTH98)
    Language English
    Publishing date 2019-03-06
    Publishing country Greece
    Document type Comparative Study ; Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.13225
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: In Vitro Study of a Liposomal Curcumin Formulation (Lipocurc™): Toxicity and Biological Activity in Synovial Fibroblasts and Macrophages.

    Kloesch, Burkhard / Gober, Lukas / Loebsch, Silvia / Vcelar, Brigitta / Helson, Lawrence / Steiner, Guenter

    In vivo (Athens, Greece)

    2016  Volume 30, Issue 4, Page(s) 413–419

    Abstract: Background/aim: The polyphenol curcumin is produced in the rhizome of Curcuma longa and exhibits potent anti-inflammatory, antioxidant, and chemopreventive activities. Due to the fact that curcumin is poorly soluble in water, many delivery systems have ... ...

    Abstract Background/aim: The polyphenol curcumin is produced in the rhizome of Curcuma longa and exhibits potent anti-inflammatory, antioxidant, and chemopreventive activities. Due to the fact that curcumin is poorly soluble in water, many delivery systems have been developed to improve its solubility and bioavailability achieving optimum therapeutic application. In this study, we evaluated the biological effects of a liposomal curcumin formulation (Lipocurc™) on human synovial fibroblasts (SW982) and mouse macrophages (RAW264).
    Material and methods: Cellular uptake of liposomes was studied using calcein-loaded liposomes. Effects of Lipocurc™ on cell viability and proliferation were determined with Celltox green cytotoxicity assay and 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay, respectively. To induce cytokine/chemokine expression, the cells were stimulated with interleukin (IL)1β or lipopolysaccharide (LPS). The release of IL6, IL8, and tumor necrosis factor-alpha (TNFα) was quantified by enzyme-linked immunosorbent assay (ELISA).
    Results: Data showed that the liposomal curcumin formulation Lipocurc™ was significantly less toxic to synovial fibroblasts and macrophages compared to non-encapsulated, free curcumin. Furthermore, Lipocurc™ effectively reduced pro-inflammatory cytokine/chemokine expression in synovial fibroblasts as well as in macrophages without affecting cell viability, suggesting that this curcumin nanoformulation might be a promising tool for the treatment of inflammatory diseases.
    MeSH term(s) Animals ; Anti-Inflammatory Agents, Non-Steroidal/pharmacology ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Curcumin/pharmacology ; Cytokines/metabolism ; Enzyme-Linked Immunosorbent Assay ; Fibroblasts/drug effects ; Fibroblasts/metabolism ; Fibroblasts/pathology ; Humans ; In Vitro Techniques ; Lipopolysaccharides/pharmacology ; Liposomes/chemistry ; Macrophages/drug effects ; Macrophages/metabolism ; Macrophages/pathology ; Mice ; NF-kappa B/metabolism ; Synovial Fluid/chemistry
    Chemical Substances Anti-Inflammatory Agents, Non-Steroidal ; Cytokines ; Lipopolysaccharides ; Liposomes ; NF-kappa B ; Curcumin (IT942ZTH98)
    Language English
    Publishing date 2016-07
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 807031-3
    ISSN 1791-7549 ; 0258-851X
    ISSN (online) 1791-7549
    ISSN 0258-851X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2288: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Erythropoietin preconditioning improves clinical and histologic outcome in an acute spinal cord ischemia and reperfusion rabbit model.

    Simon, Florian Hans Peter / Erhart, Philipp / Vcelar, Brigitta / Scheuerle, Angelika / Schelzig, Hubert / Oberhuber, Alexander

    Journal of vascular surgery

    2016  Volume 64, Issue 6, Page(s) 1797–1804

    Abstract: Objective: This study examined effects and functional outcome of recombinant human erythropoietin (rhEPO) and carbamylated erythropoietin fusion protein (cEPO-FC) preconditioning in a rabbit model for spinal cord ischemia and resulting paraplegia. This ... ...

    Abstract Objective: This study examined effects and functional outcome of recombinant human erythropoietin (rhEPO) and carbamylated erythropoietin fusion protein (cEPO-FC) preconditioning in a rabbit model for spinal cord ischemia and resulting paraplegia. This model was chosen because only a small surgical effect is needed to cause paraplegia in rabbits, which facilitates postoperative observation of animals.
    Methods: Anesthetized but spontaneously breathing New Zealand White rabbits randomly received cEPO-FC (50 μg/kg; n = 8), rhEPO (5000 IU/kg; n = 10), or vehicle (control; n = 10) 30 minutes before and after infrarenal aortic clamping. Ideal clamping time of 22 minutes was identified from preceding clamping tests (15-25 minutes). Postoperative observation time was 96 hours. Spinal cord function was assessed by neurologic evaluation of hind limb motor function every 12 hours using a modified Tarlov score. Spinal cord tissue damage was evaluated after 96 hours using hematoxylin and eosin, elastica van Gieson, Nissl, Masson-Goldner, and hemosiderin staining. Plasma levels of cell senescence markers stathmin, chitinase 1/3, elongation factor 1-α were determined.
    Results: Rabbits that received rhEPO showed significant improvement of spontaneous lower limb movements until 36 hours of reperfusion and improved histologic scores upon examination of the lumbar spinal cord compared with the control group. In contrast, cEPO-FC treatment showed comparable outcome to the control group concerning movements of the lower limbs and histology. Senescence markers were elevated in the control group, but not in the treatment groups, except for chitinase 3 in the rhEPO group. Only stathmin showed no significant effect. Markers for senescence might increase after acute ischemic injury. Attenuation of senescence markers might not come alone from improvement of the spinal cord.
    Conclusions: Preconditioning with rhEPO attenuates ischemia/reperfusion injury of the spinal cord, whereas the carbamylated derivative (cEPO-FC) showed no positive effect on spinal cord function.
    MeSH term(s) Animals ; Biomarkers/blood ; Cellular Senescence/drug effects ; Chitinases/blood ; Disease Models, Animal ; Erythropoietin/analogs & derivatives ; Erythropoietin/pharmacology ; Male ; Motor Activity ; Neurologic Examination ; Neuroprotective Agents/pharmacology ; Paraplegia/physiopathology ; Paraplegia/prevention & control ; Peptide Elongation Factor 1/blood ; Rabbits ; Recombinant Proteins/pharmacology ; Reperfusion Injury/blood ; Reperfusion Injury/pathology ; Reperfusion Injury/physiopathology ; Reperfusion Injury/prevention & control ; Spinal Cord/drug effects ; Spinal Cord/metabolism ; Spinal Cord/pathology ; Spinal Cord/physiopathology ; Spinal Cord Ischemia/blood ; Spinal Cord Ischemia/pathology ; Spinal Cord Ischemia/physiopathology ; Spinal Cord Ischemia/prevention & control ; Stathmin/blood ; Time Factors
    Chemical Substances Biomarkers ; Neuroprotective Agents ; Peptide Elongation Factor 1 ; Recombinant Proteins ; Stathmin ; carbamylated erythropoietin ; Erythropoietin (11096-26-7) ; Chitinases (EC 3.2.1.14)
    Language English
    Publishing date 2016-12
    Publishing country United States
    Document type Comparative Study ; Journal Article
    ZDB-ID 605700-7
    ISSN 1097-6809 ; 0741-5214
    ISSN (online) 1097-6809
    ISSN 0741-5214
    DOI 10.1016/j.jvs.2015.10.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1933: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application.

    Wolzt, Michael / Gouya, Ghazeleh / Sator, Michael / Hemetsberger, Thomas / Irps, Charlotte / Rettenbacher, Manfred / Vcelar, Brigitta

    European journal of drug metabolism and pharmacokinetics

    2016  Volume 41, Issue 3, Page(s) 259–265

    Abstract: Recombinant human follicle stimulating hormone (r-hFSH) is effective and safe for controlled ovarian stimulation. Bemfola(®) (Finox AG, Burgdorf, Switzerland), a new biosimilar r-hFSH, has proven comparable non-clinical pharmacological profiles to those ... ...

    Abstract Recombinant human follicle stimulating hormone (r-hFSH) is effective and safe for controlled ovarian stimulation. Bemfola(®) (Finox AG, Burgdorf, Switzerland), a new biosimilar r-hFSH, has proven comparable non-clinical pharmacological profiles to those of the widely used Gonal-f(®) (Serono Pharma S.p.A., Bari, Italy). The objective of this study was to show that Bemfola(®) yields comparable clinical pharmacokinetic (PK) and safety profiles to Gonal-f(®) in healthy female subjects. In this randomized, Phase I trial conducted in healthy female volunteers (N = 32), a 2-period, balanced 2-treatment crossover design was used. A single subcutaneous dose of 225 IU Bemfola(®) or Gonal-f(®) was administered in each treatment period per sequence. Blood was collected for pharmacokinetic analysis until 10 days after each r-hFSH treatment. For down-regulation of endogenous FSH subjects were given a depot injection with leuprolide acetate prior to the study drug in either sequence. Pharmacokinetic data was available for 23 subjects. No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)]. Subgroup analysis for estradiol (E2) response was similar for Bemfola(®) and Gonal f(®) (AUC(0--120) p = 0.21 and C max p = 0.82). No major safety issues were identified and no immunogenic reaction to r-hFSH was observed. The results of this study indicate that a single dose of Bemfola(®) exhibits pharmacokinetic and safety profiles comparable to Gonal-f(®) in healthy young women.
    MeSH term(s) Administration, Cutaneous ; Adolescent ; Adult ; Biosimilar Pharmaceuticals/adverse effects ; Biosimilar Pharmaceuticals/pharmacokinetics ; Cross-Over Studies ; Down-Regulation/drug effects ; Estradiol/metabolism ; Female ; Follicle Stimulating Hormone, Human/adverse effects ; Follicle Stimulating Hormone, Human/pharmacokinetics ; Humans ; Leuprolide/chemistry ; Ovulation Induction/methods ; Recombinant Proteins/adverse effects ; Recombinant Proteins/pharmacokinetics ; Young Adult
    Chemical Substances Biosimilar Pharmaceuticals ; Follicle Stimulating Hormone, Human ; Recombinant Proteins ; follitropin alfa ; Estradiol (4TI98Z838E) ; Leuprolide (EFY6W0M8TG)
    Language English
    Publishing date 2016-06
    Publishing country France
    Document type Clinical Trial, Phase I ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 196729-0
    ISSN 2107-0180 ; 0398-7639 ; 0378-7966
    ISSN (online) 2107-0180
    ISSN 0398-7639 ; 0378-7966
    DOI 10.1007/s13318-015-0257-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1236: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia.

    Bolger, Gordon T / Licollari, Albert / Tan, Aimin / Greil, Richard / Pleyer, Lisa / Vcelar, Brigitta / Majeed, Muhammad / Sordillo, Peter

    Anticancer research

    2018  Volume 38, Issue 1, Page(s) 121–130

    MeSH term(s) Cell Survival/drug effects ; Curcumin/administration & dosage ; Curcumin/analogs & derivatives ; Curcumin/metabolism ; Curcumin/pharmacology ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Leukocytes, Mononuclear/metabolism ; Liposomes
    Chemical Substances Liposomes ; tetrahydrocurcumin (00U0645U03) ; Curcumin (IT942ZTH98)
    Language English
    Publishing date 2018
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc

    Greil, Richard / Greil-Ressler, Sigrun / Weiss, Lukas / Schönlieb, Charlotte / Magnes, Teresa / Radl, Bianca / Bolger, Gordon T / Vcelar, Brigitta / Sordillo, Peter P

    Cancer chemotherapy and pharmacology

    2018  Volume 82, Issue 4, Page(s) 695–706

    Abstract: Purpose: This study was conducted to investigate the safety and tolerability of increasing doses of liposomal curcumin in patients with metastatic cancer. Investigations of anti-tumor activity and of the pharmacokinetics of curcumin were secondary ... ...

    Abstract Purpose: This study was conducted to investigate the safety and tolerability of increasing doses of liposomal curcumin in patients with metastatic cancer. Investigations of anti-tumor activity and of the pharmacokinetics of curcumin were secondary objectives.
    Methods: In this phase I, single-center, open-label study in patients with metastatic tumors, liposomal curcumin was administered as a weekly intravenous infusion for 8 weeks. Dose escalation was started at 100 mg/m
    Results: 32 patients were treated. No dose-limiting toxicity was observed in 26 patients at doses between 100 and 300 mg/m
    Conclusion: 300 mg/m
    MeSH term(s) Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/pathology ; Curcumin/administration & dosage ; Curcumin/adverse effects ; Curcumin/pharmacokinetics ; Dose-Response Relationship, Drug ; Drug Monitoring/methods ; Drug Tolerance ; Drug-Related Side Effects and Adverse Reactions/blood ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/etiology ; Female ; Hemoglobins/analysis ; Hemolysis/drug effects ; Humans ; Male ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Metastasis/drug therapy ; Neoplasm Metastasis/pathology ; Neoplasm Staging ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/pathology ; Treatment Outcome
    Chemical Substances Antineoplastic Agents ; Hemoglobins ; Curcumin (IT942ZTH98)
    Language English
    Publishing date 2018-08-03
    Publishing country Germany
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 6820-2
    ISSN 1432-0843 ; 0344-5704 ; 0943-9404
    ISSN (online) 1432-0843
    ISSN 0344-5704 ; 0943-9404
    DOI 10.1007/s00280-018-3654-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1420: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance.

    Bolger, Gordon T / Licollari, Albert / Tan, Aimin / Greil, Richard / Vcelar, Brigitta / Majeed, Muhammad / Helson, Lawrence

    Anticancer research

    2017  Volume 37, Issue 7, Page(s) 3483–3492

    Abstract: Background/aim: The aim of this study was to investigate the distribution of curcumin (in the form of Lipocurc™) and its major metabolite tetrahydrocurcumin (THC) in Beagle dog and human red blood cells, peripheral blood mononuclear cells (PBMC) and ... ...

    Abstract Background/aim: The aim of this study was to investigate the distribution of curcumin (in the form of Lipocurc™) and its major metabolite tetrahydrocurcumin (THC) in Beagle dog and human red blood cells, peripheral blood mononuclear cells (PBMC) and hepatocytes.
    Materials and methods: Lipocurc™ was used as the source of curcumin for the cell distribution assays. In vitro findings with red blood cells were also compared to in vivo pharmacokinetic data available from preclinical studies in dogs and phase I clinical studies in humans.
    Results: High levels of curcumin were measured in PBMCs (625.5 ng/g w.w. cell pellet or 7,297 pg/10
    Conclusion: There was an excellent correlation between the in vitro disposition of curcumin and THC following incubation with red blood cells and in vivo plasma levels of curcumin and THC in dog and human following intravenous infusion. The disposition of curcumin in blood cells is, therefore, species-dependent and of pharmacokinetic relevance.
    MeSH term(s) Animals ; Curcumin/analogs & derivatives ; Curcumin/metabolism ; Curcumin/pharmacokinetics ; Dogs ; Erythrocytes/metabolism ; Hepatocytes/metabolism ; Humans ; Infusions, Intravenous ; Leukocytes, Mononuclear/metabolism ; Plasma/metabolism ; Species Specificity
    Chemical Substances tetrahydrocurcumin (00U0645U03) ; Curcumin (IT942ZTH98)
    Language English
    Publishing date 2017
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.11716
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Conference proceedings: Preclinical small animal model for studying ischemia-reperfusion injury of the spinal cord after crossclamping of the aorta and the beneficial effect of EPO on the neuronal function

    Simon, Florian / Erhart, Philipp / Schelzig, Hubert / Vcelar, Brigitta / Oberhuber, Alexander

    2015  , Page(s) 15dgch469

    Event/congress 132. Kongress der Deutschen Gesellschaft für Chirurgie; München; Deutsche Gesellschaft für Chirurgie; 2015
    Keywords Medizin, Gesundheit
    Publishing date 2015-04-24
    Publisher German Medical Science GMS Publishing House; Düsseldorf
    Document type Conference proceedings
    DOI 10.3205/15dgch469
    Database German Medical Science

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals.

    Bolger, Gordon T / Licollari, Albert / Tan, Amin / Greil, Richard / Vcelar, Brigitta / Greil-Ressler, Sigrun / Weiss, Lukas / Schönlieb, Charlotte / Magnes, Teresa / Radl, Bianca / Majeed, Muhammed / Sordillo, Peter P

    Cancer chemotherapy and pharmacology

    2018  Volume 83, Issue 2, Page(s) 265–275

    Abstract: Purpose: Investigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the pharmacokinetics of curcumin and plasma levels of THC between cancer patients and healthy ... ...

    Abstract Purpose: Investigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the pharmacokinetics of curcumin and plasma levels of THC between cancer patients and healthy individuals following intravenous infusion of Lipocurc™ (liposomal curcumin).
    Methods: Correlation analysis was used to determine the impact of co-medication on infusion rate normalized plasma levels of curcumin and THC in cancer patients and to compare the plasma levels of curcumin and THC at different infusion rates between cancer patients and healthy individuals. In vitro hepatocyte and red blood cell distribution experiments were conducted with Lipocurc™ to support clinical findings. Plasma concentration time data were analyzed by the non-compartmental method to determine and compare the pharmacokinetic parameters of curcumin in cancer patients and healthy individuals.
    Results: Of 44 co-medications studied, three medications targeting the renin-angiotensin system, Lisinopril, Ramipril, and Valsartan elevated plasma levels of curcumin and THC in three cancer patients infused with Lipocurc™. Cell distribution experiments indicated that the disposition of curcumin in red blood cells may be a target for elevation of the plasma levels of curcumin. Plasma levels of curcumin in cancer patients increased to a greater extent with increased infusion rate compared to healthy individuals. Upon termination of infusion, the elimination phase for curcumin was shorter with a shorter terminal half-life and smaller volume of distribution for curcumin in cancer patients compared to healthy individuals.
    Conclusion: Either co-medications or health status, or both, can impact the pharmacokinetics of curcumin infusion (as Lipocurc™) in cancer patients.
    MeSH term(s) Animals ; Case-Control Studies ; Cells, Cultured ; Curcumin/administration & dosage ; Curcumin/analogs & derivatives ; Curcumin/chemistry ; Curcumin/pharmacokinetics ; Dogs ; Drug Therapy, Combination ; Erythrocytes/drug effects ; Erythrocytes/metabolism ; Healthy Volunteers ; Hepatocytes/drug effects ; Hepatocytes/metabolism ; Humans ; Infusions, Intravenous ; Liposomes/administration & dosage ; Male ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Tissue Distribution
    Chemical Substances Liposomes ; tetrahydrocurcumin (00U0645U03) ; Curcumin (IT942ZTH98)
    Language English
    Publishing date 2018-11-14
    Publishing country Germany
    Document type Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 6820-2
    ISSN 1432-0843 ; 0344-5704 ; 0943-9404
    ISSN (online) 1432-0843
    ISSN 0344-5704 ; 0943-9404
    DOI 10.1007/s00280-018-3730-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1420: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top